Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.88)
# 3,120
Out of 4,944 analysts
41
Total ratings
47.37%
Success rate
1.26%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $111.00 | +35.14% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $25.66 | +211.77% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $10.60 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $75.34 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $8.66 | +38.57% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $48.05 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $49.78 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $5.47 | +539.85% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $119.31 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $637.40 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $38.22 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $111.00
Upside: +35.14%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $25.66
Upside: +211.77%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $10.60
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $75.34
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $8.66
Upside: +38.57%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $48.05
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $49.78
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $5.47
Upside: +539.85%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $119.31
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $637.40
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $38.22
Upside: -